| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8686437 | Neurobiology of Disease | 2018 | 11 Pages |
Abstract
In conclusion, our results fully confirm the validity of A2ARs as a new target for NPC1 treatment. As soon as new ligands with improved pharmacokinetic characteristics (i.e. orally active, with brain bioavailability and metabolic stability) will be obtained, A2AR agonists could represent a breakthrough in the treatment of NPC.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Antonella Ferrante, Antonella Pezzola, Andrea Matteucci, Antonella Di Biase, Lucilla Attorri, Monica Armida, Alberto Martire, Yijuang Chern, Patrizia Popoli,